Supplier to Physiotherapists, General Public, the NHS & Armed Forces
HER2-Positive Breast Cancer

HER2-Positive Breast Cancer

Not rated yet
0

Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.

66   – Reward points
Availability: MD - Manufactured on demand
    • 10% off
    £73.99, save £7.40
  • £66.59
Qty:  
  • Shipping info

    Our publishing partner, Elsevier, maintains a flat fee for shipping. Books are delivered in the UK via DHL and will require a signature upon delivery.

    The standard delivery time within the UK is 2 working days from the date of invoice.

    Manufactured on demand titles (Availability: MD) take an extra 3-5 working days.

    At this time we only ship Elsevier book orders to addresses within the UK.

    Brexit: We have been informed that some couriers are now charging additional fees for importing from the UK into the EU. The customer is responsible for the payment of any import duties that are in addition to the shipping costs already charged.

  • Payment methods

    logos-payments-tab_1.png

Background/testing

1. The HER2 alteration in breast cancer

2. HER2 testing in the era of changing guidelines

Advanced Disease

3. Optimal first-line treatment of HER2+ advanced disease

4. Second line therapy and beyond

5. HER2+ CNS metastases

Therapeutics

6. Neoadjuvant therapy

7. Adjuvant therapy

8. Outcomes based on HR status in early stage disease

9. De-escalation of therapy for small tumor

Toxicity considerations

10. Cardiac toxicity of HER2-targeted regimens

11. Non-cardiac toxicity of HER2-targeted therapy

Therapies on the horizon

12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)

13. Harnessing the immune system in HER2+ disease

14. Biosimilars

    • SKU
      9780323581226
    • UPC/ISBN
      9780323581226
    • Stock Last Checked
      Aug 18, 2022
  • Manufacturer
    Elsevier
  • Publication Date
    Aug 2, 2018
Customer reviews
There are no comments yet. Be the first to leave a comment
Please sign in to add review

Your Elsevier book orders are actioned within 48hrs during the working week. If any one item in your purchase is delayed we will send you what is in stock and will send on the remainder as soon as it arrives. This is provided at no additional shipping cost to you. Stock availability levels are updated on a daily basis.  We ship directly from a UK warehouse.

Manufactured on demand titles (Availability: MD) take an extra 3-5 working days.

Shipping Costs

We currently maintain a flat fee structure for shipping book titles from Elsevier. Buy as many Elsevier titles as you like the we will still charge you the same single item shipping fee.

Overview Delivery Methods

Books are delivered in the UK via DHL and will require a signature upon delivery.

Deliveries within the UK

  • The standard delivery time within the UK is 2 working days from the date of invoice.
  • Print on demand titles take 3-5 working days.

Where is my order? Order Tracking

To find out more information about your order, select from the relevant options below:

Deliveries to the UK and UK shippers

Your order should be delivered to you/your shipper within 2-3 working days.

To track any deliveries using DPD, click here.

If your order is for a print on demand title, your delivery time will be longer, please allow an extra 3-5 working days.

We accept the following payment methods:

Elsevier maintains a standard returns policy